Advertisement

Utility of neuromuscular blockade reversal in the evaluation of acute neurosurgical patients: A retrospective case-series

      Highlights

      • Lingering rocuronium effects affect perceived patient neurologic status.
      • Rocuronium lingering effects can be prolonged in acute neurosurgical patients.
      • Rocuronium reversal can drastically impact neurosurgical decision making.
      • Sugammadex can serve as a useful tool in acute neurosurgical settings.

      Abstract

      Objective

      Sugammadex reversal of neuromuscular blocking agents (NMBAs) is usually performed postoperatively. A scarcity of literature exists exploring sugammadex use for timely neurological examination of neurosurgical patients. NMBAs, like rocuronium, are used in the Emergency Department during intubation and their unpredictable duration of action often impedes timely and accurate assessment of patient neurological status. We aim to explore the role of sugammadex in evaluating patients in need of acute neurosurgical care.

      Methods

      Retrospective assessment of patients presenting with traumatic brain injury or intracranial hemorrhage was conducted at our level 1 trauma center. Patients of interest were those for whom sugammadex reversal of rocuronium neuromuscular blockade, from intubating doses, was pursued to ensure timely neurologic assessment. Nine patients were identified for whom GCS pre-/post-sugammadex, rocuronium dosing, elapsed time between rocuronium administration and reversal, and clinical course data were retrieved.

      Results

      Arrival GCS was 5.2 ± 3.2, with intubation accomplished within 10 ± 2.5 min of presentation. Rocuronium dosing was consistent between patients, average single dose of 1.2 ± 0.3 mg/kg. Lingering neuromuscular blockade ranged from 28 to 132 min (87.3 ± 34.3 min). All patients exhibited a GCS of 3 T upon initial neurosurgical evaluation, prior to reversal. Post-reversal GCS rose to 6.0 T ± 2.2. Sugammadex facilitated more accurate clinical decision making in 8 of 9 patients, including prevention of unnecessary invasive procedures. Two of 9 patients were eventually discharged home or to a rehabilitation facility.

      Conclusions

      Rocuronium neuromuscular blockade can linger beyond pharmacokinetic predictions, thus delaying timely and precise neurologic assessment. Our data suggests sugammadex may be a useful addition to the clinician’s armamentarium for acute neurologic assessment in the neurosurgical population. Sugammadex may impact clinical decision-making in certain patients and allow for more informed decision-making by families and physicians alike. Prospective studies are needed to definitively assess the impact of sugammadex on outcomes in acute neurosurgical settings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Orso D.
        • Vetrugno L.
        • Federici N.
        • D'Andrea N.
        • Bove T.
        Endotracheal intubation to reduce aspiration events in acutely comatose patients: a systematic review.
        Scand J Trauma Resusc Emerg Med. 2020; 28: 116
        • Curley J.M.
        • Ciceri D.P.
        • Culp W.C.
        Sugammadex administration to facilitate timely neurologic examination in the traumatic brain injury patient.
        Neurocrit Care. 2020; 32: 880-882
        • Miller J.N.
        Neurologic function and neuromuscular blocking agents in critical care.
        Crit Care Nurs Q. 1995; 18: 74-84
        • He H.
        • Yu Z.
        • Zhang J.
        • Cheng W.
        • Long Y.
        • Zhou X.
        • et al.
        Bilateral dilated nonreactive pupils secondary to rocuronium infusion in an ARDS patient treated with ECMO therapy: A case report.
        Medicine (Baltimore). 2020; 99: e21819
        • Mohamadpour M.
        • Whitney K.
        • Bergold P.J.
        The importance of therapeutic time window in the treatment of traumatic brain injury.
        Front Neurosci. 2019; 13: 07
        • Stollings J.L.
        • Diedrich D.A.
        • Oyen L.J.
        • Brown D.R.
        Rapid-sequence intubation: a review of the process and considerations when choosing medications.
        Ann Pharmacother. 2014; 48: 62-76
        • Robertson E.N.
        • Driessen J.J.
        • Booij L.H.D.J.
        Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure.
        Eur J Anaesthesiol. 2005; 22: 4-10
        • Magorian T.
        • Flannery K.B.
        • Miller R.D.
        Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients.
        Anesthesiology. 1993; 79: 913-918
        • Claudius C.
        • Karacan H.
        • Viby-Mogensen J.
        Prolonged residual paralysis after a single intubating dose of rocuronium.
        Br J Anaesth. 2007; 99: 514-517
        • Morales Martin A.C.
        • Vaquero Roncero L.M.
        • Muriel V.C.
        Extremely prolonged neuromuscular blockade after rocuronium: a case report.
        Acta Anaesthesiol Scand. 2009; 53: 957-959
        • Moriwaki K.
        • Kayashima K.
        Prolonged neuromuscular blockade and insufficient reversal after sugammadex administration in cesarean section under general anesthesia: a case report.
        JA Clin Rep. 2019; 5: 28
        • Lee H.J.
        • Kim K.S.
        • Jeong J.S.
        • Kim K.N.
        • Lee B.C.
        The influence of mild hypothermia on reversal of rocuronium-induced deep neuromuscular block with sugammadex.
        BMC Anesthesiol. 2015; 15: 7
        • Lee L.A.
        • Athanassoglou V.
        • Pandit J.J.
        Neuromuscular blockade in the elderly patient.
        J Pain Res. 2016; 9: 437-444
        • Magorian T.
        • Wood P.
        • Caldwell J.
        • et al.
        The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease.
        Anesth Analg. 1995; 80: 754-759
        • Donati F.
        Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia.
        Expert Opin Pharmacother. 2008; 9: 1375-1386
        • Nag K.
        • Singh D.R.
        • Shetti A.N.
        • Kumar H.
        • Sivashanmugam T.
        • Parthasarathy S.
        Sugammadex: A revolutionary drug in neuromuscular pharmacology.
        Anesth Essays Res. 2013; 7: 302-306
        • Carney N.
        • Totten A.M.
        • O'Reilly C.
        • Ullman J.S.
        • Hawryluk G.W.J.
        • Bell M.J.
        • et al.
        Guidelines for the management of severe traumatic brain injury.
        Fourth Edition Neurosurgery. 2017; 80: 6-15
      1. Chandrasekhar K, Togioka BM, Jeffers JL. Sugammadex. StatPearls. Treasure Island (FL)2022.

      2. Jain A, Wermuth HR, Dua A, Singh K, Maani CV. Rocuronium. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

        • Iwasaki H.
        • Renew J.R.
        • Kunisawa T.
        • Brull S.J.
        Preparing for the unexpected: special considerations and complications after sugammadex administration.
        BMC Anesthesiology. 2017; 17: 140
        • Beaufort A.M.
        • Wierda J.M.
        • Belopavlovic M.
        • Nederveen P.J.
        • Kleef U.W.
        • Agoston S.
        The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans.
        Eur J Anaesthesiol Suppl. 1995; 11: 95-106
        • Levin N.M.
        • Fix M.L.
        • April M.D.
        • Arana A.A.
        • Brown 3rd, C.A.
        • Investigators N.
        The association of rocuronium dosing and first-attempt intubation success in adult emergency department patients.
        CJEM. 2021; 23: 518-527
        • Naguib M.
        • Brull S.J.
        • Kopman A.F.
        • Hunter J.M.
        • Fülesdi B.
        • Arkes H.R.
        • et al.
        Consensus statement on perioperative use of neuromuscular monitoring.
        Anesth Analg. 2018; 127: 71-80
        • Paton F.
        • Paulden M.
        • Chambers D.
        • Heirs M.
        • Duffy S.
        • Hunter J.M.
        • et al.
        Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
        Br J Anaesth. 2010; 105: 558-567
        • Deyhim N.
        • Beck A.
        • Balk J.
        • Liebl M.G.
        Impact of sugammadex versus neostigmine/glycopyrrolate on perioperative efficiency.
        CEOR. 2020; 12: 69-79
      3. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev 2017;8:CD012763.

        • Ezri T.
        • Boaz M.
        • Sherman A.
        • Armaly M.
        • Berlovitz Y.
        Sugammadex: an update.
        J Crit Care Med (Targu Mures). 2016; 2: 16-21
        • Dirkmann D.
        • Britten M.W.
        • Pauling H.
        • Weidle J.
        • Volbracht L.
        • Görlinger K.
        • et al.
        Anticoagulant effect of sugammadex: just an in vitro artifact.
        Anesthesiology. 2016; 124: 1277-1285
        • Kam P.-J.
        • Galta R.E.
        • Kruithof A.C.
        • Fennema H.
        • Lierop M.-J.
        • Mihara K.
        • et al.
        No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.
        Int J Clin Pharmacol Ther. 2013; 51: 976-985
        • Kam P.-J.
        • Kruithof A.C.
        • Lierop M.-J.
        • Moerland n.M.
        • Dennie J.
        • Troyer M.D.
        • et al.
        Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
        Int J Clin Pharmacol Ther. 2014; 52: 631-641
        • Takazawa T.
        • Mitsuhata H.
        • Mertes P.M.
        Sugammadex and rocuronium-induced anaphylaxis.
        J Anesth. 2016; 30: 290-297